Nathan Hall
About Nathan Hall
Nathan Hall serves as the Director of Tax at Doximity, bringing extensive experience from his previous roles at PwC and Genesys. He specializes in ASC 740 accounting for income taxes and has worked with various companies across multiple industries.
Current Role at Doximity
Nathan Hall serves as the Director of Tax at Doximity, a position he has held since 2022. In this role, he oversees tax strategies and compliance for the organization. His responsibilities include managing tax-related processes and ensuring adherence to relevant regulations. His experience in the field contributes to Doximity's financial operations, particularly in the healthcare sector.
Previous Experience at PwC
Nathan Hall has an extensive background with PricewaterhouseCoopers (PwC), where he held various positions over several years. He worked as a Tax Director from 2018 to 2022 in San Jose, California, and as a Tax Senior Manager in Dublin, Ireland, from 2019 to 2020. His earlier roles at PwC included Tax Manager, Senior Associate, and Associate, where he gained significant experience in tax accounting and compliance.
Education and Expertise
Nathan Hall earned his Bachelor of Science in Accounting and a Master of Science in Taxation from California Polytechnic State University-San Luis Obispo. His academic background provides a strong foundation for his expertise in ASC 740 accounting for income taxes and tax software implementation. He is also a member of the American Institute of CPAs, which reflects his commitment to professional development in the field.
International Restructuring and Tax Audits
Nathan Hall has been involved in international restructuring, focusing on reorganizing company structures to enhance profitability and efficiency. He has also managed large-scale carve-outs and handled multiyear income tax audits, demonstrating his capability in navigating complex tax regulations and compliance issues over extended periods.
Diverse Industry Experience
Throughout his career, Nathan Hall has worked with a variety of companies, including development stage pharmaceutical firms, established medical device companies, recent IPO SaaS businesses, and Fortune 500 multinational corporations. This diverse experience has equipped him with a broad understanding of the tax implications across different industries.